Τίτλος:
Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
From September to October 2019, seven patients colonised or infected with a ceftazidime-avibactam (CZA)-resistant Klebsiella pneumoniae carbapenemase (KPC)-2-producing K. pneumoniae were detected in two intensive care units of a Greek general hospital. The outbreak strain was sequence type (ST)147 and co-produced KPC-2 and the novel plasmid-borne Vietnamese extended-spectrum ?-lactamase (VEB)-25harbouring a K234R substitution associated with CZA resistance. Epidemiological investigations revealed that the resistance was probably acquired by horizontal transmission independently from previous CZA exposure. © 2020 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
Συγγραφείς:
Galani, I.
Karaiskos, I.
Souli, M.
Papoutsaki, V.
Galani, L.
Gkoufa, A.
Antoniadou, A.
Giamarellou, H.
Περιοδικό:
Eurosurveillance
Εκδότης:
European Centre for Disease Prevention and Control (ECDC)
Λέξεις-κλειδιά:
avibactam plus ceftazidime; antiinfective agent; avibactam, ceftazidime drug combination; azabicyclo derivative; beta lactamase; ceftazidime, adult; aged; antibiotic resistance; Article; bacterial gene; bacterial strain; bacterium identification; bacterium isolation; bacterium mutant; clinical article; epidemic; extended spectrum beta lactamase producing Klebsiella pneumoniae; female; Greece; human; Klebsiella pneumoniae carbapenemase 2; male; middle aged; minimum inhibitory concentration; nonhuman; phenotype; stop codon; Vietnamese extended spectrum beta lactamase; whole genome sequencing; wild type; antibiotic resistance; bacterial genome; drug combination; drug effect; enzymology; epidemic; genetics; intensive care unit; isolation and purification; Klebsiella infection; Klebsiella pneumoniae; metabolism; microbial sensitivity test; microbiology; mutation; very elderly, Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Disease Outbreaks; Drug Combinations; Drug Resistance, Bacterial; Female; Genome, Bacterial; Greece; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Whole Genome Sequencing
DOI:
10.2807/1560-7917.ES.2020.25.3.2000028
